Is Now Available!
- Nobelpharma America launches patient support program, Nobelpharma Connect (September 2022)
- HYFTORTM (sirolimus topical gel) 0.2%, Now Available in the U.S (August 30, 2022)
Contribute to Society by Developing Critical but Neglected Pharmaceuticals and Medical Devices.
We contribute to society by developing drugs and medical devices for diseases that other pharmaceutical companies may overlook because of the small number of patients affected or for other reasons, and to deliver these drugs and devices where they are needed.
We will continue to further evolve by developing First-In-Class & Best-In-Class drugs and launch products in more regions, such as the United States and Europe.
Message from the President & CEO
Nobelpharma America, LLC is the first global subsidiary of Nobelpharma Co., Ltd. in Tokyo, Japan for the purpose of expanding our business to the United States.
Nobelpharma collaborates with worldwide experts to strive to bring products to the markets as quickly as possible with the hopes of providing patients and physicians with treatments that are greatly needed.
“Critical but neglected – That is precisely why it must be created”
Nobelpharma was established in 2003 in Tokyo, Japan to fulfill the following mission:
“Contribute to medical care by developing, manufacturing and delivering essential medicines that other companies might not pursue.”
In Japan, Nobelpharma obtained several approvals for the manufacture and sales of new drugs*; the success rate in a little more than 10 years in Japan is on par with large pharmaceutical companies. We take much pride in the corporate philosophy that is unique to Nobelpharma that made this possible.
This website contains information about products that may not be available in the U.S. Nothing contained herein should be considered a solicitation, promotion or advertisement for any product including those under development.